Drug intelligence / Profile preview

Canghuo Pingwei Granules

Development stage: Unknown
Lead developer: Shanxi Xinbaoyuan Pharmaceutical
Administration: Oral

Overview

Canghuo Pingwei Granules is a Traditional Chinese Medicine (TCM) candidate developed by Hefei Innovation Pharmaceutical Technology Co., Ltd. for the treatment of dyspepsia associated with chronic superficial gastritis. The formulation specifically targets the "spleen and stomach damp-heat syndrome" (脾胃湿热证) according to TCM diagnostic criteria. It is likely derived from or related to the classic Pingwei San formula, incorporating botanical components such as Atractylodis Rhizoma (Cang Zhu) and Agastachis Herba (Huo Xiang) to resolve dampness and harmonize the stomach. The drug is administered orally as a granule formulation and has been evaluated in Phase II clinical trials in China to assess its efficacy and safety over an 8-week treatment period.

Other names: 苍藿平胃颗粒

Beyond the preview

Go deeper on Canghuo Pingwei Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canghuo Pingwei Granules.

Explore the full profile